Auris Medical (EARS) Sees Large Volume Increase

Shares of Auris Medical Holding AG (NASDAQ:EARS) saw unusually-high trading volume on Thursday . Approximately 2,332,993 shares traded hands during trading, an increase of 33% from the previous session’s volume of 1,757,758 shares.The stock last traded at $0.37 and had previously closed at $0.35.

Several equities analysts have recently weighed in on the stock. ValuEngine raised shares of Auris Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research raised shares of Auris Medical from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a research report on Tuesday, January 1st. Finally, Roth Capital assumed coverage on shares of Auris Medical in a research report on Thursday, December 20th. They issued a “buy” rating and a $5.00 price objective on the stock.

WARNING: “Auris Medical (EARS) Sees Large Volume Increase” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/4204738/auris-medical-ears-sees-large-volume-increase.html.

Auris Medical Company Profile (NASDAQ:EARS)

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Featured Story: Cost of Goods Sold (COGS)